KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Inovio Pharmaceuticals (INO) Receivables - Other (2016 - 2023)

Inovio Pharmaceuticals' Receivables - Other history spans 14 years, with the latest figure at $5.0 million for Q1 2023.

  • For Q1 2023, Receivables - Other rose 42.29% year-over-year to $5.0 million; the TTM value through Mar 2023 reached $5.0 million, up 42.29%, while the annual FY2022 figure was $10.0 million, 291.26% up from the prior year.
  • Receivables - Other for Q1 2023 was $5.0 million at Inovio Pharmaceuticals, down from $10.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $10.0 million in Q4 2022 and bottomed at $346974.0 in Q1 2021.
  • The 5-year median for Receivables - Other is $1.3 million (2019), against an average of $2.7 million.
  • The largest annual shift saw Receivables - Other tumbled 62.18% in 2020 before it soared 905.01% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $1.3 million in 2019, then crashed by 62.18% to $503782.0 in 2020, then soared by 409.19% to $2.6 million in 2021, then surged by 291.26% to $10.0 million in 2022, then crashed by 50.56% to $5.0 million in 2023.
  • Per Business Quant, the three most recent readings for INO's Receivables - Other are $5.0 million (Q1 2023), $10.0 million (Q4 2022), and $7.6 million (Q3 2022).